Longeveron Inc
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
BFCXX BlackRock Liquidity FedFund Fund Capital
VTR Ventas Inc
LTC LTC Properties Inc
CNK Cinemark Holdings Inc
TITN Titan Machinery Inc
AHL-C Aspen Insurance Holdings Ltd
EVBN Evans Bancorp Inc
CTXS Citrix Systems Inc
RY Royal Bank of Canada

Health Care : Biotechnology | Small Cap Value
Company profile

Longeveron Inc. is a clinical stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. It is sponsoring phase I and II clinical trials in various indications, such as aging frailty, Alzheimer's disease (AD), metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). It is evaluating Lomecel-B as a therapy for aging frailty and is being designed to reduce inflammation associated with aging frailty and to promote an anti-inflammatory state by releasing anti-inflammatory molecules, which can promote physiological restoration to a more normal state. The Company has completed two multicenter trials in the United States for aging frailty.

Day's Change
-0.9099 (-9.98%)
B/A Size
Day's High
Day's Low

Today's volume of 212,099 shares is on pace to be much lighter than LGVN's 10-day average volume of 384,047 shares.

  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    3:10p ET 05/18/22
  • Last (size)
  • 52-Wk Range
    2.84 - 45.00
  • (11/17/21 - 11/24/21)
  • 220.0%
  • Market Cap
  • Shares Outstanding
  • -0.90
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • --
  • 11.38
  • (% of float 04/29/22)

Latest News

May 13, 2022
8:00 am ET
Globe Newswire
May 09, 2022
4:15 pm ET
Globe Newswire
8:30 am ET
Globe Newswire
April 14, 2022
8:58 am ET
Globe Newswire
April 13, 2022
3:28 pm ET
Globe Newswire
8:30 am ET
PR Newswire
8:00 am ET
Globe Newswire
April 05, 2022
8:00 am ET
Globe Newswire
March 31, 2022
8:45 am ET
PR Newswire
8:00 am ET
Globe Newswire
March 24, 2022
8:00 am ET
Globe Newswire
7:41 am ET
March 15, 2022
8:00 am ET
Globe Newswire
March 11, 2022
8:00 am ET
Globe Newswire
March 07, 2022
8:00 am ET
Globe Newswire
March 02, 2022
8:00 am ET
Globe Newswire
November 22, 2021
3:42 pm ET
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.